硫唑嘌呤治疗炎症性肠病发生淋巴瘤的风险研究进展

Abstract
Figure/Table
References (34)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract In recent years,there have been more and more reports of lymphoma in patients with inflammatory bowel disease (IBD).Most studies have recognized that patients with IBD have a low risk of developing lymphoma,but the risk of lymphoma significantly increases in those patients treated with Azathioprine (AZA).At present,the adverse reactions of AZAwhich is the most commonly used as immunosuppressant in IBD patients have attracted more and more attention from clinicians.This article reviews not only the risk and possible mechanisms of lymphoma induced by AZAin patients with IBD,but also the clinical benefits and precautions of IBD patients treated with AZA,so as to help clinicians improve the understanding of the disease.

Key words： Inflammatory bowel disease Azathioprine Lymphoma Treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHEN Yan-li
	ZHANG An-xing
	LUO Juan
	MIAO Ying-lei▲

Cite this article:

SHEN Yan-li,ZHANG An-xing,LUO Juan, et al. Research progress of lymphoma risk in inflammatory bowel disease treated with Azathioprine[J]. 中国当代医药, 2020, 27(5): 19-22.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I5/19

[1]	Adam L，Phulukdaree A，Soma P.Effective long-term solution to therapeutic remission in inflammatory bowel disease：Role of Azathioprine[J].Biomed Pharmacother，2018，100：8-14.
[2]	Kim JH，Kim JW.Effect of immunomodulators and biologic agents on malignancy in patients with inflammatory bowel disease[J].Korean J Gastroenterol，2017，70（4）：162-168.
[3]	Godat S，Fournier N，Safroneeva E，et al.Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort[J].Eur J Gastroenterol Hepatol，2018，30（6）：612-620.
[6]	Korelitz BI.Enduring value of thiopurines for inflammatory bowel disease therapy[J].Dig Dis Sci，2017，62（2）：292-293.
[16]	曹倩.硫唑嘌呤治疗炎症性肠病——大小剂量选择原则[J].中国实用内科杂志，2018，38（3）：184-186.
[4]	Lewis JD，Bilker WB，Brensinger C，et al.Inflammatory bowel disease is not associated with an increased risk of lymphoma[J].Gastroenterology，2001，121（5）：1080-1087.
[5]	Wheat CL，Clark-Snustad K，Devine B，et al.Worldwide incidence of colorectal cancer，leukemia，and lymphoma in inflammatory bowel disease：an updated systematic review and Meta-analysis[J].Gastroenterol Res Pract，2016，2016：1 632 439.
[7]	Johnson CM，Dassopoulos T.Update on the use of thiopurines and methotrexate in inflammatory bowel disease[J].Curr Gastroenterol Rep，2018，20（11）：53.
[8]	Lemaitre M，Kirchgesner J，Rudnichi A，et al.Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease[J].JAMA，2017，318（17）：1679-1686.
[9]	Kotlyar DS，Lewis JD，Beaugerie L，et al.Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine：a meta-analysis[J].Clin Gastroenterol Hepatol，2015，13（5）：847-858.e4；quiz e48-50.
[10]	Khan N，Abbas AM，Lichtenstein GR，et al.Risk of lymphoma in patients with ulcerative colitis treated with thiopurines：a nationwide retrospective cohort study[J].Gastroenterology，2013，145（5）：1007-1015.e3.
[11]	Beigel F，Steinborn A，Schnitzler F，et al.Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies[J].Pharmacoepidemiol Drug Saf，2014，23（7）：735-744.
[12]	Barzilai M，Polliack A，Avivi I，et al.Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease：Portrait of a rare clinical entity[J].Leuk Res，2018，71：1-5.
[13]	Smith A，Crouch S，Lax S，et al.Lymphoma incidence，survival and prevalence 2004-2014：sub-type analyses from the UK′s Haematological Malignancy Research Network[J].Br J Cancer，2015，112（9）：1575-1584.
[14]	Beaugerie L，Brousse N，Bouvier AM，et al.Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease：a prospective observational cohort study[J].Lancet，2009，374（9701）：1617-1625.
[15]	Lord JD，Shows DM.Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease[J].World J Gastroenterol，2017，23（18）：3240-3251.
[17]	Pavlovska K，Petrushevska M，Gjorgjievska K，et al.Importance of 6-thioguanine nucleotide metabolite monitoring in inflammatory bowel disease patients treated with Azathioprine[J].Pril（Makedon Akad Nauk Umet Odd Med Nauki），2019，40（1）：73-79.
[18]	Wong DR，Coenen MJ，Vermeulen SH，et al.Early assessment of thiopurine metabolites identifies patients at risk of thiopurine-induced leukopenia in inflammatory bowel disease[J].J Crohns Colitis，2017，11（2）：175-184.
[19]	Chapman S，El-Matary W.Screening for Epstein-Barr virus statusandriskofhemophagocyticlymphohistiocytosisinchildren with inflammatory bowel disease on Azathioprine[J].Gastroenterology，2017，153（4）：1167-1168.
[20]	Li X，Chen N，You P，et al.The status of Epstein-Barr virus infection in intestinal mucosa of Chinese patients with inflammatory bowel disease[J].Digestion，2019，99（2）：126-132.
[21]	Bermejo F，Aguas M，Chaparro M，et al.Recommendations of the Spanish Working Group on Crohn′s Disease and Ulcerative Colitis（GETECCU）on the use of thiopurines in inflammatory bowel disease[J].Gastroenterol Hepatol，2018，41（3）：205-221.
[22]	De Boer NKH，Peyrin-Biroulet L，Jharap B，et al.Thiopurines in inflammatory bowel disease：new findings and perspectives[J].J Crohns Colitis，2018，12（5）：610-620.
[23]	Treton X，Bouhnik Y，Mary JY，et al.Azathioprine withdrawal in patients with Crohn′s disease maintained on prolonged remission：a high risk of relapse[J].Clin Gastroenterol Hepatol，2009，7（1）：80-85.
[24]	Broekman MMTJ，Coenen MJH，Wanten GJ，et al.Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype[J].Aliment Pharmacol Ther，2017，46（10）：953-963.
[25]	Pashazadeh P，Marjani A，Asadi J，et al.Thiopurine methyltransferase genetic polymorphisms and activity and metabolic products of Azathioprine in patients with inflammatory bowel disease [J].Endocr Metab Immune Disord Drug Targets，2019，19（4）：541-547.
[26]	Quezada SM，McLean LP，Cross RK.Adverse events in IBD therapy：the 2018 update[J].Expert Rev Gastroenterol Hepatol，2018，12（12）：1183-1191.
[27]	Sánchez Rodríguez E，Ríos León R，Mesonero Gismero F，et al.Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease[J].Gastroenterol Hepatol，2018，41（10）：629-635.
[28]	Hanauer SB，Sandborn WJ，Lichtenstein GR.Evolving considerations for thiopurine therapy for inflammatory bowel diseases-a clinical practice update：commentary[J].Gastroenterology，2019，156（1）：36-42.
[29]	Magro F，Gionchetti P，Eliakim R，et al.Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis.Part 1：Definitions，diagnosis，extraintestinal manifestations，pregnancy，cancer surveillance，surgery，and ileo-anal pouch disorders[J].J Crohns Colitis，2017，11（6）：649-670.
[30]	Barnes EL，Herfarth HH.The usefulness of serologic testing for Epstein-Barr virus before initiation of therapy for inflammatory bowel disease[J].Gastroenterology，2017，153（4）：1167.
[31]	Honkila M，Niinimaki R，Taskinen MM，et al.A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine：a case report and review of literature[J].BMC Infect Dis，2019，19（1）：404.
[32]	Rahier JF，Magro F，Abreu C，et al.Second European evidence-based consensus on the prevention，diagnosis and management of opportunistic infections in inflammatory bowel disease[J].J Crohns Colitis，2014，8（6）：443-468.
[33]	Feng R，Guo J，Zhang SH，et al.Low 6-thioguanine nucleotide level：Effective in maintaining remission in Chinese patients with Crohn′s disease[J].J Gastroenterol Hepatol，2019，34（4）：679-685.
[34]	Estevinho MM，Afonso J，Rosa I，et al.A systematic review and Meta-analysis of 6-thioguanine nucleotide levels and clinical remission in inflammatory bowel disease[J].J Crohns Colitis，2017，11（11）：1381-1392.